The use of famotidine in the treatment of Parkinson's disease: a pilot study.
Seven patients with idiopathic Parkinson's disease were enrolled in a ten week study to evaluate the efficacy of famotidine, an histamine H2-antagonist, in the treatment of bradyphrenia. Patients received famotidine 80 mg/day for a period of six weeks and were evaluated with neuropsychological tests. Overall, patients demonstrated improvement in variables measured. Some patients also reported an improvement in their motor symptoms.
Molinari
S P
SP
Department of Neurology, Mount Sinai Medical Center, New York, NY, USA.
Kaminski
R
R
Di Rocco
A
A
Yahr
M D
MD
D000368:Aged; D003071:Cognition / Q000502:physiology; D015738:Famotidine / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D010865:Pilot Projects; D011597:Psychomotor Performance / Q000502:physiology
D006635:Histamine H2 Antagonists; D015738:Famotidine